AIFF
Firefly Neuroscience, Inc. Common StockAIFF
AIFF
About: Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders.
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.76% more ownership
Funds ownership: 0% [Q2] → 1.76% (+1.76%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for AIFF.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering with brain health illnesses by bringing objective measurement of brain activity to the front lines of healthcare.
Neutral
GlobeNewsWire
1 month ago
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024.
Neutral
GlobeNewsWire
2 months ago
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that the Board of Directors of Firefly granted 557,885 restricted shares (the “Shares”) as an inducement grant to David Johnson, the Company's Executive Chairman, pursuant to that certain Employment Agreement (the “Agreement”), by and between the Company and Mr. Johnson. The Shares were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the Agreement and the Company's 2024 Long-Term Incentive Plan.
Neutral
GlobeNewsWire
2 months ago
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform
Neutral
GlobeNewsWire
2 months ago
Firefly Neuroscience to Participate in Upcoming October Investor Conferences
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences:
Neutral
GlobeNewsWire
3 months ago
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Partnership will expand Firefly's FDA Cleared BNA™ technology to more hospitals and physician offices Partnership will expand Firefly's FDA Cleared BNA™ technology to more hospitals and physician offices
Neutral
GlobeNewsWire
4 months ago
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright's 26th Annual Global Investment Conference September 9-11
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that its Chief Executive Officer, Jon Olsen, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024.
Neutral
GlobeNewsWire
4 months ago
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced management will host a shareholder update call on Wednesday, September 4, 2024 at 5:00 PM Eastern Time.
Neutral
GlobeNewsWire
4 months ago
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
NCD Will Integrate Firefly's BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes NCD Will Integrate Firefly's BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes
Neutral
GlobeNewsWire
4 months ago
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders, today issued a letter to its stockholders from its Chief Executive Officer, Jon Olsen, following the closing of its merger transaction with WaveDancer, Inc. (NASDAQ: WAVD). Dear Fellow Firefly Stockholders, This week's closing and the addition of working capital puts us in a position to execute on our strategic objectives.
Charts implemented using Lightweight Charts™